ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback